Are Peptides Legal in North Dakota? (2026)

The federal rules that apply in North Dakota, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in North Dakota:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including North Dakota. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What North Dakota law adds

North Dakota's controlled-substances law (Uniform Controlled Substances Act, N.D. Cent. Code Chapter 19-03.1; schedules at 19-03.1-05 to 19-03.1-13) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (ndlegis.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on North Dakota's schedules or in a North Dakota-specific ban as of September 2026. That is the position in most states.

Human growth hormone

North Dakota's Schedule III lists specific anabolic steroid molecules but no human growth hormone, somatropin, chorionic gonadotropin or other peptide. HGH is a prescription drug in North Dakota with no state restriction beyond federal law. (N.D. Cent. Code 19-03.1-09 (Schedule III)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No North Dakota Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed North Dakota pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No North Dakota medical board guidance specific to peptide therapy was located. A North Dakota prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in North Dakota

N.D. Cent. Code 19-03.1-23(7) makes it unlawful to wilfully possess a controlled substance without a valid prescription, so holding unscheduled research peptides is no state controlled-substance offence; no separate North Dakota offence for possessing a non-controlled prescription drug was found in the chapter. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into North Dakota is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes, after a real examination. N.D. Cent. Code 43-17-44 requires an examination before initially diagnosing or treating, which may be done by secure videoconferencing, store-and-forward technology or through an intervening licensed provider, and says an evaluation consisting only of a static online questionnaire or an audio conversation does not meet the standard of care. After a compliant exam the licensee may prescribe non-controlled drugs such as GLP-1s. (codes.findlaw.com) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a North Dakota law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in North Dakota

• 2025-02-19. North Dakota's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. No North Dakota Board of Pharmacy, Board of Medicine or attorney general statement on compounded GLP-1s, peptides or medspas was found; board items are absent rather than confirmed absent.

Frequently asked questions

Is BPC-157 legal in North Dakota?

North Dakota has not scheduled BPC-157, so possessing it is not a North Dakota offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in North Dakota?

Yes, after a real examination. N.D. Cent. Code 43-17-44 requires an examination before initially diagnosing or treating, which may be done by secure videoconferencing, store-and-forward technology or through an intervening licensed provider, and says an evaluation consisting only of a static online questionnaire or an audio conversation does not meet the standard of care. After a compliant exam the licensee may prescribe non-controlled drugs such as GLP-1s. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in North Dakota?

Only with a valid prescription for an approved use. North Dakota does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://ndlegis.gov/cencode/t19c03-1.html
• https://codes.findlaw.com/nd/title-19-foods-drugs-oils-and-compounds/nd-cent-code-sect-19-03-1-09/
• https://codes.findlaw.com/nd/title-43-occupations-and-professions/nd-cent-code-sect-43-17-44/
• https://codes.findlaw.com/nd/title-19-foods-drugs-oils-and-compounds/nd-cent-code-sect-19-03-1-23/
• https://www.naag.org/press-releases/state-and-territory-attorneys-general-urge-fda-to-take-action-against-counterfeit-and-illegally-sold-glp-1-drugs/

Every North Dakota fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.